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Edited by Vladimir SkulachevAbstract Statins are inhibitors of the mevalonate synthesis
pathway that induce apoptosis in tumor cells although the apop-
totic mechanism activated by statins remains to be elucidated.
We have examined the role of the mitochondria-operated path-
way of apoptosis in the cell death induced by statins in breast tu-
mor cells and its regulation by protein prenylation and ErbB2
overexpression. Lovastatin treatment down-regulates the expres-
sion of Bcl-2 and activates apoptosis through a mitochondria-
operated, ErbB2- regulated mechanism. Apoptosis induced by
statins is independent of their eﬀects on cholesterol synthesis
and involves protein prenylation. Our results indicate that pre-
nylation of apoptosis-regulating proteins is a key event in the
survival of breast tumor cells and this requirement could be cir-
cumvented in cells overexpressing the oncogene ErbB2.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Prenylation1. Introduction
Blocking of mevalonate synthesis by statins, inhibitors of the
3-OH-3-methyl-glutaryl CoA (HMG-CoA) reductase, has
been used to treat hypercholesterolemia and prevent cardio-
vascular diseases [1,2]. However, statins not only reduce cho-
lesterol levels but they also aﬀect the synthesis of other
products of the mevalonate pathway such as isoprenoids,
essential components of signalling proteins involved in cell
proliferation and cancer [3–5]. Attachment of isoprenoids
compounds to protein members of the Ras/Rho family facili-
tate their anchoring to the cell membrane where they carried
out their role [6].
Clinical studies have reached mixed conclusions about the
relationship between statin use and breast cancer risk [7]. On
the other hand, statins have been shown to inhibit cell prolif-
eration and induce cell death by apoptosis in diﬀerent tumorAbbreviations: FPP, farnesylpyrophosphate ammonium salt; GGPP,
geranylgeranylpyrophosphate; PARP, poly-(ADP-ribose) polymerase;
HMG-CoA, hydroxymethylglutaryl-Coenzyme A
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doi:10.1016/j.febslet.2008.06.034cell lines [8–10]. Statins seem to induce apoptosis and inhibit
proliferation to a greater degree in malignant than in non-
malignant cells, possibly because of the increased expression
of HMG-CoA reductase and a greater requirement for meva-
lonate-derived isoprenoids in tumour as opposed to normal
cells [11]. In breast tumor cells, diﬀerent signalling pathways
have been reported to be responsible for the apoptosis induced
by statins. Nitric oxide and lipid rafts levels and JNK activa-
tion have been implicated in the proapoptotic actions of statins
[9,12]. Down-regulation of survivin and inhibition of Akt have
also been observed in statin-induced apoptosis in other tumor
cells [13,14]. However, the apoptotic mechanism activated in
breast tumor cells by statins remains to be elucidated.
The ErbB2 proto-oncogene encodes human epidermal
growth factor receptor-2 which belongs to the epidermal
growth factor receptor tyrosine kinases. Upregulation of erbB2
receptors has been found in about 25–30% breast cancer pa-
tients, which is related with poor prognosis. ErbB2 overexpres-
sion is linked to resistance to apoptosis and down-regulation
of erbB-2 receptor by trastuzumab (herceptin) enhances death
receptor-induced apoptosis [15]. In this study we show that sta-
tin treatment down-regulate Bcl-2 expression and induces
apoptosis in breast tumor cells by a mitochondria-operated
pathway. In breast tumor cells overexpressing ErbB2 apopto-
sis by statin is clearly inhibited. Apoptosis induced by statins
in breast tumor cells is independent of their eﬀects on choles-
terol synthesis and requires the prenylation of proteins.2. Materials and methods
2.1. Reagents and antibodies
Caspase inhibitor benzyloxy-carbonyl-Val-Ala-Asp-(OMe) ﬂuorom-
ethyl ketone (Z-VAD-FMK) was from Bachem, AG (Bachem, Buben-
dorf, Switzerland). Mevinolin (lovastatin), squalene, mevalonic acid,
mevastatin, geranylgeranylpyrophsphate (GGPP), farnesylpyrophs-
phate ammonium salt (FPP) and anti-tubulin antibody were purchased
from Sigma Chemical Corp (St. Louis, MO). Anti-human caspase-8
monoclonal antibody was purchased from Cell Diagnostica (Mu¨nster,
Germany). Anti-poly(ADP-ribose) polymerase (PARP), cytochrome c
and Bax monoclonal antibodies were from Biosciences PharMingen
(San Jose´, CA). Anti-caspase-9 and caspase-3 antibodies were from
New England Biolabs Inc. (Ipswich, MA). Anti-GAPDH antibody
was from Biogenesis (Poole, UK). Anti-ErbB2 antibody was kindly
provided by Dr. Joaquin Arribas (Vall dHebron University Hospital
Research Institute, Barcelona, Spain). Anti-Bcl-2 and secondary goat
anti-mouse and goat anti-rabbit antibodies were obtained from
DAKO (Cambridge, United Kingdom).blished by Elsevier B.V. All rights reserved.
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Stable MCF-7 cell line overexpressing human Bcl-2 protein has been
described previously [16]. MCF-7 cell line overexpressing ErbB2 was a
donation of Dr. Joaquin Arribas (Vall dHebron University Hospital
Research Institute, Barcelona, Spain). The cell lines were either main-
tained in RPMI 1640 (MDA-MB231, MCF-7) or in DMEM (MDA-
MB435S, SkBr3 and BT474) containing 10% fetal bovine serum and
1 mM L-glutamine at 37 C in humidiﬁed 5% CO2, 95% air incubator.
Culture medium of MDA-MB435S cells (DMEM) was also supple-
mented with insulin (10 lg/mL). MCF10A cells were maintained in
DMEM/F12 (1:1) containing 10% fetal bovine serum, insulin (10 Hg/
mL), EGF (20 ng/mL) and hydrocortisone (500 ng/mL).
2.3. Analysis of apoptosis
Cells (3 · 105/well) were treated with statin in 6-well plates for the
times indicated in the ﬁgure legends. After treatment, hypodiploid
apoptotic cells were detected by ﬂow cytometry according to published
procedures [16]. Basically, cells were washed with phosphate buﬀered
saline (PBS), ﬁxed in cold 70% ethanol and then stained with propidi-
um iodide while treating with RNAse. Quantitative analysis of subG1
cells was carried out in a FACSCalibur cytometer using the Cell Quest
software (Becton Dickinson, Mountain View, CA). Phosphatidylserine
(PS) exposure on the surface of apoptotic cells was examined by ﬂow
cytometry after staining with Annexin-V-FLUOS (Roche Molecular
Biochemicals, Germany), following instructions provided by the man-
ufacturer.
2.4. Viability assay
Cells (3.5 · 103/well) were treated with statin in 24-well plates for the
times indicated in the ﬁgure legends. After treatment, cells were washed
with PBS and stained with 0.2% Crystal Violet in 2% Ethanol for
20 min at room temperature. Absorbance of the samples was deter-
mined using a multiplate reader Varioskan Flask (Termo Electron
Corporation).
2.5. Cellular fractionation
Cells (3 · 105/well) were treated with statin in 6-well plates for the
times indicated in the ﬁgure legends. After treatment, cells were de-
tached from the plate with RPMI/EDTA and trypsin, washed with
PBS and lysed in 30 ll ice cold lysis buﬀer (80 mM KCl, 250 mM su-
crose, 500 lg/ml digitonin and protease inhibitors in PBS). For mea-
surements of cytochrome c and Bax, cell lysates were centrifuged for
5 min at 10000 · g to separate the supernatant (cytosolic fraction)
and pellet (mitochondria-containing fraction). Amount of protein in
each fraction was determined by the Bradford protein assay (Bio-
Rad, Hertfordshire, UK). Proteins from the supernatant and pellet
were mixed with Laemmli buﬀer and resolved on SDS–12% PAGE
minigels. Cytochrome c and Bax were determined by Western blot
analysis.
2.6. Detection of proteins by Western blot analysis
Cells (3 · 105/well) were treated with statin in 6-well plates for the
times indicated in the ﬁgure legends. After treatment, cells were de-
tached from the plate with RPMI/EDTA and trypsin, washed with
PBS and lysed in 20 ll of Laemmli buﬀer. Samples were sonicated
and proteins were resolved on SDS–polyacrylamide minigels and de-
tected as described previously [17].
2.7. Statistical analysis
All data are presented as the means ± S.E. of at least three indepen-
dent experiments. The diﬀerences among diﬀerent groups were deter-
mined by the Students t-test. P < 0.05 was considered signiﬁcant.3. Results and discussion
3.1. Lovastatin induces apoptosis in human breast tumor cells
Antitumor properties of statins have been extensively evalu-
ated [7]. Despite these studies, there are still important contro-
versies regarding the beneﬁcial eﬀects of statins on breast
tumor prevention. On the other hand, antiproliferative andproapoptotic actions of statins on breast tumor cells have been
recently examined [9,18,19]. However, the molecular mecha-
nism by which statins induce apoptosis in breast tumor cells re-
mains unknown. In this report, we have examined the eﬀect of
the lypophilic statin lovastatin on the mitochondrial pathway
of apoptosis in breast tumor cells. Lovastatin-induced apopto-
sis in a dose and time-dependent manner in the breast tumor
cell line MDA-MB231 as determined by measuring the per-
centage of hypodiploid cells (Fig. 1A). Activation of apoptosis
by lovastatin was also observed in the highly metastatic breast
tumor cell line MDA-MB435S (Fig. 1B). In contrast, at the
doses used in these experiments the ErbB2-overexpressing
breast tumor cell lines BT474 and SKBr-3 were very resistant
to lovastatin-induced apoptosis (Fig. 1B). To further investi-
gate the importance of ErbB2 overexpression on the resistance
of breast tumor cells to statin-induced apoptosis, we per-
formed a number of experiments with MCF-7 cells that has
been transfected with a cDNA encoding for the oncogene
ErbB2. These cells stably overexpress ErbB2 as can be seen
in Fig. 1C. Next, we examined the eﬀect of lovastatin treat-
ment in control and ErbB2-overexpressing MCF-7 cells. Re-
sults shown in Fig. 1C demonstrate that MCF-7/ErbB2 cells
are markedly resistant to lovastatin treatment as determined
by analysis of phosphatidylserine exposure on the surface of
apoptotic cells after staining with Annexin-V-FLUOS and cell
viability with crystal violet. Interestingly, the immortalised hu-
man breast epithelial cell line MCF10A was also markedly
resistant to the proapoptotic eﬀect of lovastatin (not shown).
3.2. Lovastatin induces the activation of a caspase-dependent,
mitochondria-operated pathway of apoptosis in breast
tumor cells
To further establish the mechanism of lovastatin-promoted
cell death, we examined the caspase dependency of this cell
death process. We found that the generation of subG1 cells
induced by lovastatin was dependent on caspase activation
as it was completely prevented by the general caspase inhibitor
Z-VAD-fmk (Fig. 2A). To conﬁrm that the apoptosis cascade
was fully active in MDA-MB231 cells treated with lovastatin
and that caspase activation was involved in the process, we
analyzed the proteolytic degradation of the nuclear protein
PARP, a substrate of executioner caspases. As shown in
Fig. 2B, PARP cleavage was clearly induced in cells treated
with lovastatin. Moreover, we observed that the initiator
caspases in the extrinsic and intrinsic pathways of apoptosis
(caspase-8 and caspase-9) were activated by lovastatin in
MDA-MB231 (Fig. 2C) and MCF-7 cells (not shown). After
a 48 h-treatment with lovastatin, caspase-3, an executioner
caspase, was also activated in the MDA-MB231 cell line
(Fig. 2C).
To examine the mechanism of lovastatin-induced apoptosis
we ﬁrst analysed the activation of a mitochondria-controlled
apoptotic pathway by lovastatin in breast tumor cells. To this
end we determined the translocation of cytosolic Bax to mito-
chondria and the release of cytochrome c from this organelle.
Analysis by Western blotting of cytosolic and mitochondria-
containing subcellular fractions revealed that treatment of
breast tumor MCF-7 cells with lovastatin induced the loss of
cytochrome c from the mitochondrial fraction and the translo-
cation of Bax from the cytosol to the mitochondria-containing
fraction (Fig. 3A). Interestingly, in MCF-7 cells overexpressing
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Fig. 1. Lovastatin induces apoptosis in breast tumor cells. (A) MDA-MB231 cells were seeded in 6-well plates (3 · 105 cells/well) and treated with
lovastatin as indicated either for 24 h or for 48 h in medium containing 0.5% foetal bovine serum. After this incubation apoptosis was assessed by
measuring the percentage of hypodiploid cells in the culture. Results show the means ± S.E. of three independent experiments. (B) MDA-MB435s,
MDA-MB231, BT474 and SBr3 cells were seeded in 6-well plates (3 · 105 cells/well) and treated with lovastatin (5 or 20 lM) in medium containing
0.5% foetal bovine serum. The percentage of apoptotic cells with sub-G1 DNA content are shown and the values represent means ± S.E. of three
independent experiments. (C) MCF7 control and MCF7-overexpressing ErbB2 cells were seeded in 6-well plates (3 · 105 cells/well, Annexin-V-Fluos)
or 24-well plates (3.5 · 103/well, crystal violet) and treated with lovastatin (5 or 20 lM) in medium containing 0.5% foetal bovine serum. The
percentage of cells with externalization of phosphatidylserine (Annexin-V-Fluos) or cell viability (crystal violet) are shown and the values represent
means ± S.E. of four independent experiments. Immunoblot detection of ErbB2 expression is also shown.
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Fig. 2. Caspase-dependent activation of a mitochondria-operated
pathway of apoptosis by lovastatin in breast tumor cells. (A) MDA-
MB231 cells were seeded in 6-well plates (3 · 105 cells/well) and
incubated with or without Z-VAD-fmk (100 lM) 1 h before the
addition of lovastatin. After 48 h, apoptosis was determined as
indicated in Fig. 1A. Results show the means ± S.E. of three
independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001 as com-
pared to cells without z-VAD-fmk (B) Total lysates from MDA-
MB231 cells (3 · 105) treated with lovastatin (100 lM) for 48 h in the
presence of 10% serum were analyzed by immunoblotting for PARP
cleavage. a-Tubulin levels were used as a loading control. Similar
results were obtained in two independent experiments. (C) MDA-
MB231 cells were seeded in 6-well plates (3 · 105/well) and treated with
lovastatin (100 lM in the presence of 10% serum) for either 24 h or
48 h. Total protein was harvested and caspase processing was
determined by Western blot analysis. Similar results were obtained in
two independent experiments.
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further insight into the mechanism of lovastatin-induced apop-
tosis we studied the expression levels of Bcl-2 in breast tumorcells treated with this statin. Western blots revealed that at 24 h
and 48 h after the addition of lovastatin there was a decrease in
the expression of Bcl-2 protein in MCF-7 and MDA-MB231
cells (Fig. 3B). These data suggest that inhibiting HMG-CoA
reductase activity in breast tumor cells caused the down-regu-
lation of antiapoptotic Bcl-2 protein that in turn promoted the
activation of a mitochondria-operated pathway of apoptosis.
3.3. Statin-induced apoptosis requires geranylgeranylation and
farnesylation of proteins but not the synthesis of cholesterol
We next studied the relevance of the inhibition by lovastatin
of mevalonate synthesis, the immediate downstream product
of HMG-CoA reductase, on apoptosis. Interestingly, the
apoptosis-inducing eﬀects of lovastatin in both MDA-MB231
and MDA-MB435S cells were prevented by the presence of
mevalonate in the culture medium (Fig. 4A), which indicate
that lovastatin-induced apoptosis was a consequence of inhibi-
tion of HMG-CoA reductase. We also examined the role of the
cholesterol pathway in the apoptosis induced by lovastatin. As
shown in Fig. 4A addition of squalene, an intermediate in the
pathway leading to cholesterol synthesis did not prevent lova-
statin-induced apoptosis. Similar results were obtained with
mevastatin (Fig. 4B), a statin produced by the mould Penicil-
lium citrinium. Mevastatin at doses of 5 and 20 lM induced
apoptosis in MDA-MB231 cells and these eﬀects were pre-
vented by mevalonate added to the culture medium but not
by cholesterol intermediate squalene.
The synthesis of cholesterol is a complex multi-step process
[3]. Isoprenoids are important intermediates in the cholesterol
biosynthetic pathway that serve as lipid attachments for a vari-
ety of signalling molecules, such as heterotrimeric G-proteins
and the small GTP-binding proteins Ras and its related Ras-
like proteins, such as Rho, Rac, Rab, Rap and Ral. Farnesyl
pyrophosphate (FPP) and geranylgeranyl pyrophosphate
(GGPP), two isoprenoids compounds produced in the choles-
terol synthesis pathway, are bound to several cellular proteins,
including small GTPases by a post-translational modiﬁcation
known as isoprenylation. This process involves the addition
of a 15-carbon farnesyl chain in FPP (farnesylation) or a 20-
carbon geranylgeranyl chain in GGPP (geranylgeranylation)
to a cysteine sulfhydryl group near the carboxyl terminus. By
inhibiting HMG-CoA reductase, statins can prevent the bio-
synthesis of isoprenoids such as FPP and GGPP. As a conse-
quence, the diverse actions of the small GTP-binding proteins
are reduced. To elucidate how statins were activating apoptosis
in breast tumor cells, we examined the role of prenylation of
proteins in the apoptosis induced by lovastatin and mevastatin
in MDA-MB231 cells. We incubated the cells with the isopre-
noids derivatives geranylgeranylpyrophosphate (GGPP) or
farnesylpyrophosphate (FPP) and determined the sensitivity
to statin-induced apoptosis. As shown in Fig. 4C, when cells
were pretreated with GGPP or FPP and treated with lovastatin
or mevastatin, statin-induced apoptosis was strongly reduced.
Therefore, when protein prenylation is restored after statin
treatment, apoptosis is not observed. These results indicate
the importance of the inhibition of protein prenylation in the
apoptotic cell death induced by statins in breast tumor cells.
The translocation of Ras to the cell membrane is necessary
for activity and is dependent on farnesylation. Similarly,
attachment of Rho and Rac to the cell membrane is required
for activity but, in contrast to Ras, these factors undergo ger-
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esylation or geranylgeranylation of proteins is suﬃcient to pre-
vent statin-induced apoptosis in breast tumor cells suggest that
diﬀerent members of the small GTP-binding proteins family
are involved in the mechanism of apoptosis induction by stat-
ins. An alternative explanation for these results is the unusual
property of RhoB among prenylated proteins that can be farn-
esylated or geranylgeranylated [20]. Inhibition of small GTP-
binding proteins prenylation by statins could aﬀect various sig-
nalling pathways regulating cell survival [21]. In this respect, a
role of Rho inhibition in the antitumor and proapoptotic ef-
fects of statins by inhibiting Rho-dependent NF-kB activation
has been reported [19]. Abrogation of cell adhesion to the
extracellular matrix has also been observed in cells treated with
statins and this could aﬀect cell survival [22].
We have observed that breast tumor cells overexpressing
ErbB2 are markedly more resistant to the proapoptotic eﬀects
of statins than other breast tumor cell lines. Ampliﬁcation or
overexpression of ErbB2 in cancer cells confers resistance to
apoptosis and promotes cell growth through Akt activation
[23]. It has been recently shown that statins synergistically in-
duce tumor cell death with inhibitors of the PI3K/Akt pathway
[24]. Our results may indicate that in breast tumor cells
expressing elevated levels of ErbB2 the constitutive activation
of survival pathways like PI3K/Akt, MAPK/Erk1/2 and NF-
kB may render these cells resistant to the proapoptotic eﬀects
of statins. In this context, statins could be valuable tools as
antitumor agents in combination with pharmacological inhib-
itors of these survival pathways.
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